Hi everyone,
I’m Jaione Maiz, Ph.D, MBA, a Principal at Anzu focusing on investing at the intersections of life science and innovative technology. I’m happy to share some recent updates about our portfolio company, NTx, a life sciences company that is redefining biomanufacturing and changing the way biologic medicines are produced.
In March, we welcomed Jamie Coffin, Ph.D., as CEO. He brings more than 20 years’ leadership experience in health care and life sciences. NTx co-founder Alex Koglin, Ph.D. was named President and Chief Science Officer, in addition serving on the Board of Directors. NTx also appointed Sheila Moran as Chief Commercial Officer, Phillip Easton, Ph.D. as Vice President of IT Infrastructure and Operations, and Lily Pisani as Senior Director of Customer Excellence. The team in Rio Rancho, New Mexico, has expanded to thirty-six personnel. The leadership team continues to drive R&D, manufacturing, commercialization, and partnership efforts of its game-changing biomanufacturing platform.
NTx’s proprietary platform is helping pharmaceutical companies accelerate the production of biologics and vaccines (think RNA, protein therapeutics, insulin and the flu and COVID-19 vaccines). Anzu developed conviction in NTx because we believe that the technology is more efficient than currently used industry methods, resulting in higher quality yields and less waste, at a lower cost.
Today, most biologic medicines are made using a traditional “batch” production process, which, like cooking a complicated dinner recipe, requires many different (and expensive) pieces of equipment, space, and talent. The work that goes into the cell culture process – including upstream, to program the biological cells (to increase the amount of desired product compared to byproducts), and downstream (to purify the product away from the cellular biomass and byproducts) – is burdensome.
NTx simplifies this process by offering a continuous flow, table-top solution that eliminates the need for cellular engineering or cell maintenance. This novel approach minimizes the handling of materials in the batch process and the exposure to potential contamination. The result is a faster and more efficient solution capable of producing high-quality RNA (and eventually proteins) at both micro (e.g. personalized mRNA cancer vaccines) or macro (e.g. pandemic preparedness and response) manufacturing scales.
The enabling technology at the heart of NTx’s RNA production solution, called NTxScribe™, is a hollow-fiber bioreactor. This hollow tube allows for the efficient interaction between the underlying DNA template, from which RNA is made, and the specialized enzymes and nucleotides, the building blocks of DNA and RNA. This interaction enables the translation of the DNA blueprint into the functional RNA, including mRNA and next-generation forms of RNA like self-amplifying RNA (aka saRNA or samRNA). NTx is also using similar underlying inventions to advance this technology to enable the production of proteins from that RNA.
NTx is currently working with top pharma, biotech, vaccine, and government partners, including DARPA and BARDA, to help provide the essential materials (the actual mRNA, saRNA and critical ingredients) that are sometimes challenging to produce. NTx is also engaging with partners interested in its next-generation protein-production technology.
Simply put, NTx’s technology platforms are changing the way medicines are manufactured. We believe that the company has a dynamic, flexible technology that can quickly scale from personalized medicines volumes of RNA to global pandemic response quantities using the same table-top system and single operator.
NTx’s vision is to democratize the production of RNA and proteins – and its mission is to revolutionize biomanufacturing to expand access to life saving RNA and protein therapies.
If you have any questions, and or know of any partners that could be interested, please don’t hesitate to reach out.
Sincerely,
Dr. Jaione Maiz, Principal
|
|